Treatment with Insulin Secretagogues and Cancer-Related Mortality in Type 2 Diabetic Patients A Retrospective Cohort Study

Abstract

Insulin secretagogues and, to a lesser extent, exogenous insulin, appear to be associated with increased mortality for cancer, even after adjustment for multiple confounders. This issue deserves further investigation through epidemiological studies on larger samples of patients.